Does monolaurin have better evidence than docosanol?
No clinical advantage for monolaurin is established by the sources reviewed here. Docosanol has randomized human cold-sore trials; the cited monolaurin work investigates antiviral activity in laboratory systems.25 These studies do not directly compare the two treatments in people.
What the docosanol trials measured
In two pooled randomized, placebo-controlled studies, 370 adults received docosanol 10% cream and 367 received placebo. Treatment began during early symptoms or redness. Median healing time was 4.1 days with docosanol, 18 hours shorter than with placebo (95% confidence interval for the difference: 2–22 hours). Adverse experiences were mild and similar between groups.2 This is an average comparison of study groups, not a guaranteed improvement for every person.
A smaller earlier trial also investigated early and later treatment.3 The current US drug label emphasizes starting at the first sign of a cold sore for best results.8 Our earlier statement that the treatment window necessarily closes once blisters form was too categorical.
Why the mechanisms do not rank the treatments
Cell experiments indicate that docosanol inhibits fusion between the viral envelope and the host-cell membrane.1 Glycerol monolaurate and related lipids have been investigated for effects on enveloped viruses in laboratory assays.45 Neither description establishes which approach would heal a cold sore faster.
The 2020 GML study tested HIV-1 and several other viruses; its herpes discussion draws on earlier lipid research.5 It should not be described as a human cold-sore trial or as proof that a cream destroys HSV on contact in a lesion.
How to read conflicting evidence
A 2009 review questioned the size of docosanol's benefit.6 A guinea-pig study found no significant benefit of docosanol over its vehicle in that model. The authors cautioned that the model could miss clinical effects mediated through other mechanisms.7 Those findings belong alongside the human trial results; an animal experiment cannot replace a human comparison.
Evidence side by side
| Question | Docosanol | Monolaurin |
|---|---|---|
| Human healing outcomes | Randomized cold-sore trials; a modest benefit in the pooled study.2 | Not established by the cited laboratory studies.5 |
| Timing or regimen | Defined in the drug label.8 | The reviewed sources do not establish a cold-sore application regimen. |
| Safety interpretation | Trial observations and product-specific warnings.28 | Cannot be inferred from food use or membrane activity. Mouse vaginal-exposure findings raise a formulation-specific concern.9 |
| Head-to-head superiority | No direct human comparison is provided by these sources. | |
What remains unknown
The reviewed evidence does not establish whether a defined monolaurin formulation helps human cold sores, what concentration or schedule to use, or how its benefits and harms compare with docosanol. A proposed mechanism and a natural origin cannot answer those questions. This article compares research; it does not recommend replacing an established treatment with monolaurin.
See monolaurin and cold sores for the laboratory evidence and the safety discussion for dose and route limitations.